Could This Study Be Bad News for Pfizer's COVID Vaccine Sales?
Pfizer (NYSE: PFE) stated earlier this month that it expects its COVID-19 vaccine will generate sales of close to $26 billion this year. More revenue is on the way beyond 2021. For example, Pfizer and its partner BioNTech (NASDAQ: BNTX) recently announced a new deal with the European Union to supply up to 1.8 billion additional doses through 2023.
However, the dynamics of the COVID-19 vaccine market are constantly changing. Last week, researchers in Spain reported results from a clinical study that included Pfizer's COVID-19 vaccine. Could these results be bad news for future sales of Pfizer's vaccine?
Image source: Getty Images.
Source Fool.com
